Research ArticlePediatric Rheumatology

Safety and Efficacy of Rituximab in Severe Juvenile Dermatomyositis: Results from 9 Patients from the French Autoimmunity and Rituximab Registry

BRIGITTE BADER-MEUNIER, HÉLÈNE DECALUWE, CHRISTINE BARNERIAS, ROMAIN GHERARDI, PIERRE QUARTIER, ALBERT FAYE, VINCENT GUIGONIS, ANNE PAGNIER, KARINE BROCHARD, JEAN SIBILIA, JACQUES-ERIC GOTTENBERG and CHRISTINE BODEMER
The Journal of Rheumatology July 2011, 38 (7) 1436-1440; DOI: https://doi.org/10.3899/jrheum.101321

REFERENCES

  1. 1.↵
    1. Feldman BM,
    2. Rider LG,
    3. Reed AM,
    4. Pachman LM
    . Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201–12.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Khanna S,
    2. Reed AM
    . Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve 2010;41:581–92.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Chung L,
    2. Genovese MC,
    3. Fiorentino DF
    . A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763–7.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Touma Z,
    2. Arayssi T,
    3. Kibbi L,
    4. Masri AF
    . Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008;75:334–7.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Haroon M,
    2. Devlin J
    . Rituximab as a first-line agent for the treatment of dermatomyositis. Rheumatol Int 2010 Mar 26. [Epub ahead of print]
  6. 6.↵
    1. Levine TD
    . Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601–7.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Dinh HV,
    2. McCormack C,
    3. Hall S,
    4. Prince HM
    . Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007;56:148–53.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Noss EH,
    2. Hausner-Sypek DL,
    3. Weinblatt ME
    . Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006;33:1021–6.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Feist E,
    2. Dorner T,
    3. Sorensen H,
    4. Burmester GR
    . Long lasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 2008;35:1230–2.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Sultan SM,
    2. Ng KP,
    3. Edwards JC,
    4. Isenberg DA,
    5. Cambridge G
    . Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008;26:887–93.
    OpenUrlPubMed
  11. 11.↵
    1. Rios Fernández R,
    2. Callejas Rubio JL,
    3. Sánchez Cano D,
    4. Sáez Moreno JA,
    5. Ortego Centeno N
    . Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009;27:1009–16.
    OpenUrlPubMed
  12. 12.↵
    1. Gottenberg JE,
    2. Guillevin L,
    3. Lambotte O,
    4. Combe B,
    5. Allanore Y,
    6. Cantagrel A,
    7. et al.
    Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913–20.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Cooper MA,
    2. Willingham DL,
    3. Brown DE,
    4. French AR,
    5. Shih FF,
    6. White AJ
    . Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007;56:3107–11.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Tzaribachev N,
    2. Koetter I,
    3. Kuemmerle-Deschner JB,
    4. Schedel J
    . Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2009;2:6609.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Ardelean DS,
    2. Gonska T,
    3. Wires S,
    4. Cutz E,
    5. Griffiths A,
    6. Harvey E,
    7. et al.
    Severe ulcerative colitis after rituximab therapy. Pediatrics 2010;126:e243–6.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Voog E,
    2. Morschhauser F,
    3. Solal-Celigny P,
    4. Benyunes MC,
    5. Multani PS,
    6. Saunders A
    . Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691–3.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Carson KR,
    2. Evens AM,
    3. Richey EA,
    4. Habermann TM,
    5. Focosi D,
    6. Seymour JF,
    7. et al.
    Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834–8.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Rider LG,
    2. Giannini EH,
    3. Harris-Love M,
    4. Joe G,
    5. Isenberg D,
    6. Pilkington C,
    7. et al.
    Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603–17.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Oddis CV,
    2. Riderr LG,
    3. Reed AM,
    4. Ruperto N,
    5. Brunner HI,
    6. Konneru B,
    7. et al.
    International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52:2607–15.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Ruperto N,
    2. Pistorio A,
    3. Ravelli A,
    4. Rider LG,
    5. Pilkington C,
    6. Oliveira S,
    7. et al.
    The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res 2010;62:1533–41.
    OpenUrlCrossRef
  21. 21.↵
    1. Stringer E,
    2. Singh-Grewal D,
    3. Feldman BM
    . Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008;58:3585–92.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Willems M,
    2. Haddad E,
    3. Niaudet P,
    4. Koné-Paut I,
    5. Bensman A,
    6. Cochat P,
    7. et al.
    Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148:623–7.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. López De Padilla CM,
    2. Vallejo AN,
    3. Lacomis D,
    4. McNallan K,
    5. Reed AM
    . Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009;60:1160–72.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Huber AM,
    2. Giannini EH,
    3. Bowyer SL,
    4. Kim S,
    5. Lang B,
    6. Lindsley CB,
    7. et al.
    Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res 2010;62:219–25.
    OpenUrl
  25. 25.↵
    1. Pediatric Rheumatology INternational Trials Organization
    . Juvenile dermatomyositis trial. [Internet. Accessed March 14, 2011.] Available from: http://www.printo.it/project_ongoing_detail.asp?ProjectID=14
  26. 26.↵
    1. Rouster-Stevens KA,
    2. Morgan GA,
    3. Wang D,
    4. Pachman LM
    . Mycophenolate mofetil, a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res 2010;62:1446–51.
    OpenUrlCrossRef
  27. 27.↵
    1. Dagher R,
    2. Desjonquères M,
    3. Duquesne A,
    4. Quartier P,
    5. Bader-Meunier B,
    6. Fischbach M,
    7. et al.
    Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 2010 Dec 9. [Epub ahead of print]
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Save to my folders

Jump to section